Want to see ABSI full AI Analyst Report?
Top Page
AbSci
(NASDAQ:ABSI)
Select Model
Select Model
Rating:59Neutral
Price Target:
$9.00
▼(-6.54% Downside)
Action:Reiterated
Date:08/19/26
ABSI’s score is held back primarily by weak financial performance (minimal/declining revenue, large net losses, and heavy cash burn), partially offset by a low-debt balance sheet and a positive earnings call highlighting extended runway and encouraging early clinical PK/safety. Technicals add modest support with a strong uptrend above key moving averages, while valuation remains constrained by losses and a negative P/E.
Positive Factors
Strong liquidity and extended funding runway
The substantially increased cash position gives AbSci time to advance clinical programs and platform development without immediate financing pressure. A runway into the second half of 2028 improves planning flexibility, although future spending remains significant.
Negative Factors
Minimal and declining revenue base
Revenue remains too small to support AbSci’s research infrastructure and has not yet shown a scalable growth trend. The company therefore remains dependent on collaborations, milestones, or future product success rather than established recurring operating revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and extended funding runway
The substantially increased cash position gives AbSci time to advance clinical programs and platform development without immediate financing pressure. A runway into the second half of 2028 improves planning flexibility, although future spending remains significant.
Read all positive factors
AbSci (ABSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.65B
Dividend YieldN/A
Average Volume (3M)6.43M
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue Growth-62.28%
EPS Growth15.36%
CountryUS
Employees140
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding171,614,010
10 Day Avg. Volume3,381,155
30 Day Avg. Volume6,434,959
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.38Price Target Upside38.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$4.74M
AbSci Business Overview & Revenue Model
Company Description
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biol...
How the Company Makes Money
AbSci primarily makes money by providing R&D and drug-development collaboration services to biotechnology and pharmaceutical companies, typically structured as partnered programs where AbSci applies its AI models and laboratory workflows to design...
AbSci Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive developments: encouraging interim Phase I safety and PK data for ABS-201, a meaningful strategic investment and collaboration with Eli Lilly, a substantial financing that materially strengthened the balance sheet (cash up ~60% quarter‑over‑quarter), clear near‑term clinical milestones, and notable platform efficiency gains (Atlas/Origin). Key risks and negatives are present but limited: efficacy is not yet unblinded, durability remains to be demonstrated beyond 26 weeks, operating expenses increased modestly (~10.2% R&D; ~8.2% SG&A), and successful commercialization depends on Absci's execution despite Lilly's involvement not conferring program rights. Overall, the highlights meaningfully outweigh the lowlights given the strong cash runway, strategic partner validation, and promising PK/safety profile, though clinical proof of efficacy and durability remain the critical upcoming catalysts.Positive Updates
Positive interim Phase I safety and PK data for ABS-201
Blinded interim Phase I data indicate ABS-201 was well tolerated with a favorable safety and tolerability profile. Interim PK shows estimated half‑life of at least 65 days, supporting potential dosing of 2–3 injections over 6 months and modeling that suggests >90% prolactin receptor occupancy with that regimen.
Negative Updates
Clinical efficacy still unproven and awaiting unblinded data
Interim data are blinded and only directionally positive; unblinded efficacy results are pending. Key efficacy readouts (durability and magnitude of hair regrowth) will not be fully answered until the 26‑week data and extended follow‑up.
Read all updates
Q2-2026 Updates
Positive
Negative
Positive interim Phase I safety and PK data for ABS-201
Blinded interim Phase I data indicate ABS-201 was well tolerated with a favorable safety and tolerability profile. Interim PK shows estimated half‑life of at least 65 days, supporting potential dosing of 2–3 injections over 6 months and modeling that suggests >90% prolactin receptor occupancy with that regimen.
Read all positive updates
Company Guidance
Management guided that ABS‑201's blinded SAD data estimate a half‑life of at least 65 days supporting a 2–3 injection regimen over 6 months and modeling predicts >90% prolactin receptor occupancy with that dosing; they expect an interim proof‑of‑concept (13‑week) readout later in 2026 and full 26‑week POC in early 2027, plan to initiate a Phase II endometriosis study in Q4‑2026 with potential POC in H2‑2027, and reiterated primary endpoints (safety/tolerability) and key secondaries (PK/PD, immunogenicity, target area hair count/width/darkening and PROs). Financially, Absci completed ~ $100M financing in June including a $40M Eli Lilly strategic investment (net offering proceeds ≈ $93.6M), reported $201.1M cash and marketable securities as of 6/30/2026 (up from $125.7M on 3/31/2026) and said this funding supports operations into the second half of 2028; Q2 spend run‑rates were R&D $22.6M and SG&A $9.2M. Management also cited a target 26‑week hair‑count increase of ~30–35 hairs/cm2 (roughly on par with high‑dose oral minoxidil) underpinning a U.S. TAM > $25B and estimated peak endometriosis sales > $4B, and highlighted platform efficiencies (prior INDs <2.5 years and <$15M; Origin model ~1,000x library size reduction).AbSci Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56M | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M |
| Gross Profit | -4.00M | -8.94M | -57.92M | -41.85M | -53.16M | -39.80M |
| EBITDA | -109.92M | -103.16M | -94.10M | -79.68M | -91.36M | -67.68M |
| Net Income | -121.08M | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
Balance Sheet | ||||||
| Total Assets | 268.92M | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M |
| Cash, Cash Equivalents and Short-Term Investments | 201.14M | 144.29M | 112.42M | 97.66M | 164.43M | 252.57M |
| Total Debt | 3.68M | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M |
| Total Liabilities | 22.79M | 26.85M | 34.48M | 41.12M | 46.59M | 60.09M |
| Stockholders Equity | 246.13M | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M |
Cash Flow | ||||||
| Free Cash Flow | -108.97M | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M |
| Operating Cash Flow | -108.08M | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M |
| Investing Cash Flow | -12.72M | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M |
| Financing Cash Flow | 174.44M | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M |
AbSci Technical Analysis
Positive
9.63
Price Trends
9.15
Positive
7.09
Positive
5.07
Positive
Market Momentum
0.21
Negative
52.20
Neutral
45.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Positive. The current price of 9.63 is above the 20-day moving average (MA) of 8.93, above the 50-day MA of 9.15, and above the 200-day MA of 5.07, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 52.20 is Neutral, neither overbought nor oversold. The STOCH value of 45.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABSI.
AbSci Risk Analysis
AbSci disclosed 90 risk factors in its most recent earnings report. AbSci reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbSci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $649.42M | -2.20 | -178.58% | ― | 287.93% | -21.91% | |
59 Neutral | $1.65B | -11.53 | -59.21% | ― | -62.28% | 15.36% | |
56 Neutral | $868.44M | -5.72 | -41.33% | ― | 278712.12% | 26.59% | |
52 Neutral | $981.28M | -13.21 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $132.77M | -1.58 | 44.63% | ― | 3.03% | 57.71% |
* Healthcare Sector Average
ABSI
AbSci
9.22
6.75
273.28%
AUTL
Autolus Therapeutics
2.33
0.76
48.41%
ADCT
ADC Therapeutics
1.05
-2.20
-67.69%
FDMT
4D Molecular Therapeutics
15.56
9.38
151.78%
DSGN
Design Therapeutics
15.59
9.95
176.42%
AbSci Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Absci Highlights Positive Phase 1 Data and Financing
Positive
Aug 11, 2026
On August 11, 2026, Absci reported second-quarter 2026 results and business updates, highlighted by positive interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201. The blinded aggregate data indicated that ABS-201 was well tolerat...
Business Operations and StrategyPrivate Placements and Financing
Absci Announces $100 Million Public Equity Offering
Positive
Jun 24, 2026
On June 24, 2026, Absci priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share, for expected gross proceeds of about $100 million and estimated net proceeds of roughly $93.5 million. The deal, made under an ...
Business Operations and StrategyProduct-Related Announcements
Absci Reports Positive Phase 1 Data for ABS-201
Positive
Jun 24, 2026
On June 24, 2026, Absci reported positive interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia. In 32 healthy adults given single ascending IV doses up to 1,800 mg, A...
Executive/Board ChangesShareholder Meetings
Absci Stockholders Approve Directors and Auditor at Meeting
Neutral
Jun 5, 2026
On June 4, 2026, Absci Corporation held its Annual Meeting of Stockholders, with 155,447,428 common shares eligible to vote as of the April 7, 2026 record date. Shareholders voted on board composition and audit oversight matters that shape the com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.